AstraZeneca Results Presentation Deck
Oncology
Product Sales ($m)
800
700
600
500
400
300
200
100
☐EM
0
EROW
■ Europe
US
Q2
99
67
153
269
Lynparza
10% growth at CER to $1,368m in H1 2023
Q3
2021
96
67
155
270
Q4
103
71
161
294
Q1
121
66
160
270
Q2
120
72
169
312
2022
Q3
117
64
164
314
Q4
130
66
162
331
Due to rounding, the sum of a number of dollar values and percentages may not agree to totals.
39 CER = constant exchange rates; EM = Emerging Markets; EROW= Established Rest of World.
Collaboration partners: Merck & Co., Inc. (Lynparza).
Q1
137
68
178
268
2023
Q2
142
77
187
311
Lynparza
Collaboration Revenue: $3.8bn recorded cumulative, $3.9bn future potential
Collaboration Revenue ($m)
600
400
200
0
Sales Milestone
Regulatory Milestone
Q2
Q3
2021
Q4
400
Q1
APPENDIX | H1 2023 Product Performance
175
Q2
2022
Q3
75
Q4
105
Q1
2023
Q2
3View entire presentation